Delivering next-generation treatments for back of the eye disorders, with focus on diabetic eye disease

THR-149 - Further readings

Targeting plasma kallikrein with a novel bicyclic peptide inhibitor alleviates diabetic retinopathy disease hallmarks in a preclinical rat model
Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy.
Effects of a selective bradykinin B1 receptor antagonist on increased plasma extravasation in streptozotocin-induced diabetic rats: distinct vasculopathic profile of major key organs
Expression, distribution and function of kinin B1 receptor in the rat diabetic retina.
Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation.
Inhibitory effect of a novel bradykinin B1 receptor antagonist, R-954, on enhanced vascular permeability in type 1 diabetic mice.
Ocular application of the kinin B1 receptor antagonist LF22-0542 inhibits retinal inflammation and oxidative stress in streptozotocin-diabetic rats.
Plasma kallikrein and diabetic macular edema.
Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats.
Plasma Kallikrein Mediates Vascular Endothelial Growth Factor-Induced Retinal Dysfunction and Thickening.
Plasma Kallikrein-Kinin System as a VEGF-Independent Mediator of Diabetic Macular Edema.
Profiling of vitreous proteomes from proliferative diabetic retinopathy and nondiabetic patients.
Retinal plasma extravasation in streptozotocin-diabetic rats mediated by kinin B(1) and B(2) receptors.
Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema.
The kallikrein-kinin system in diabetic retinopathy. Prog. Drug Res. 69, 111-143.